Radiopharmaceuticals Become a Major Healthcare Investment Battleground

Radiopharmaceuticals are rapidly becoming one of the most competitive areas of healthcare investment as companies move to strengthen their positions in advanced cancer diagnosis and targeted treatment.

The latest signal came from GE HealthCare, which agreed to acquire Sofie Biosciences for $945 million. The deal will expand GE HealthCare’s ability to manufacture and distribute radiopharmaceuticals used in PET imaging and give it U.S. rights to FAPI-74, an experimental cancer-imaging agent currently in late-stage development.

Radiopharmaceuticals contain radioactive compounds that can help doctors identify disease activity inside the body. Their importance is growing particularly in oncology, where molecular imaging can help locate tumours and support more targeted treatment decisions. However, the sector presents a unique operational challenge: many radioactive products have short half-lives, making manufacturing, transportation and delivery highly time-sensitive.

That supply-chain challenge is becoming an important investment opportunity. GE HealthCare says the Sofie acquisition will give it a network of 15 U.S. manufacturing sites and 21 cyclotrons, strengthening its ability to reach hospitals closer to the point of care.

GE HealthCare is not alone. In August, Curium agreed to acquire Lantheus in a transaction valued at up to $8 billion, highlighting the scale of consolidation taking place across the sector.

As pharmaceutical and medical-technology companies compete for a larger share of radiopharmaceuticals, investment is increasingly extending beyond drug development into manufacturing, specialised facilities and distribution networks. The sector could therefore become an important part of the next phase of precision healthcare.